Keyphrases
Cirrhosis
100%
Meta-analysis
85%
Systematic Meta-analysis
73%
Non-alcoholic Fatty Liver Disease (NAFLD)
68%
Confidence Interval
52%
Hepatic Encephalopathy
50%
Type 2 Diabetes Mellitus (T2DM)
34%
Glucagon
33%
Type 2 Diabetic Patients
32%
Randomized Trial
31%
Glucagon-like
28%
Metabolic-associated Fatty Liver Disease (MAFLD)
26%
Liver
24%
Walled-off
22%
Nonalcoholic Steatohepatitis
21%
Chronic Hepatitis C
21%
Randomized Controlled Trial
21%
Placebo
20%
Acute Variceal Bleeding
20%
Meta-analysis of Randomized Controlled Trials
20%
High Risk
19%
Liver Disease
19%
Decompensated Cirrhosis
18%
Obesity
17%
Risk of Bias
17%
Hepatorenal Syndrome
16%
Transjugular Intrahepatic Portosystemic Shunt
16%
Acute-on-chronic Liver Failure
16%
Beneficial Effects
16%
Ribavirin
16%
Relative Risk
15%
Ascites
15%
Pancreatic Necrosis
15%
Risk Ratio
14%
Randomized Clinical Trial
14%
Randomized Placebo-controlled Trial
14%
Rifaximin
13%
Cochrane
13%
Non-absorbable Disaccharides
13%
Inflammatory Bowel Disease
13%
Interferon-α (IFN-α)
13%
Liver Biopsy
12%
Clinical Trials
12%
Acute Pancreatitis
12%
Receptor Agonist
12%
A1 Receptor
12%
Hyperglucagonemia
11%
Fibrosis
11%
Umbilical Hernia Repair
11%
Nonselective β-blockers
11%
Medicine and Dentistry
Liver Cirrhosis
90%
Meta-Analysis
78%
Nonalcoholic Fatty Liver
60%
Systematic Review
58%
Maturity Onset Diabetes of the Young
32%
Hepatic Encephalopathy
32%
Liver Disease
32%
Patient with Type 2 Diabetes
28%
Randomized Controlled Trial
26%
Systematic Review with Meta-Analysis
24%
Bleeding
18%
Glucagon
18%
Placebo
18%
Ascites
17%
Hepatorenal Syndrome
16%
Body Mass Index
16%
Pancreas Necrosis
16%
Fibrosis
15%
Transjugular Intrahepatic Portosystemic Shunt
14%
Glucagon Like Peptide 1
14%
Observational Study
14%
Beta Adrenergic Receptor Blocking Agent
14%
Acute Pancreatitis
13%
Randomized Clinical Trial
13%
Disease
13%
Umbilical Hernia
13%
Necrosis
13%
Hernioplasty
12%
Decompensated Liver Cirrhosis
11%
Liver Biopsy
11%
Diabetes
11%
Fatty Liver
11%
Infection
10%
Cohort Analysis
10%
Hepatocellular Carcinoma
10%
Obesity
10%
Hyperglucagonemia
10%
Esophageal Varices
10%
Adverse Event
10%
Secretion (Process)
9%
Patient Referral
9%
Acute on Chronic Liver Failure
9%
Autoimmune Liver Disease
9%
Ligation
9%
Patient-Data
9%
Clinical Trial
9%
Insulin Resistance
9%
Terlipressin
9%
Alcohol-Related Liver Disease
8%
Bariatric Surgery
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cirrhosis
56%
Hepatic Encephalopathy
42%
Non Insulin Dependent Diabetes Mellitus
33%
Nonalcoholic Fatty Liver
33%
Randomized Controlled Trial
31%
Placebo
30%
Liver Disease
24%
Acute on Chronic Liver Failure
16%
Ribavirin
16%
Ascites
15%
Chronic Hepatitis C
14%
Adverse Event
13%
Rifaximin
13%
Glucagon Like Peptide 1 Receptor Agonist
13%
Hepatorenal Syndrome
13%
Interferon
12%
Fibrosis
10%
Mercaptopurine
10%
Disaccharide
9%
Randomized Clinical Trial
9%
Clinical Trial
9%
Ammonium
9%
Bleeding
9%
Observational Study
9%
Ethanol
9%
Biological Marker
9%
Allopurinol
9%
Disease
8%
Terlipressin
8%
Monotherapy
8%
Upper Gastrointestinal Bleeding
8%
Peginterferon
8%
Inflammation
7%
Branched Chain Amino Acid
7%
Alcohol Liver Disease
7%
Liver Cell Carcinoma
7%
Decompensated Liver Cirrhosis
7%
Feces microflora
7%
Ulcerative Colitis
6%
Antioxidant
6%
Pregnancy Diabetes Mellitus
6%
Irritable Colon
6%
Acute Pancreatitis
6%
Bile Acid Sequestrant
6%
Azathioprine
6%
Umbilical Hernia
6%
Autoimmune Liver Disease
6%
Probiotic Agent
6%
Malignant Neoplasm
6%
Tranexamic Acid
6%
